Clinical Data Celgene announced long term safety data pooled from 182-week (3.5-year) safety data from the ESTEEM 1 and 2 trials and 3-year safety data from the PALACE 1-3 trials.  The pooled data showed no increases in the severity or frequency of adverse events and no new safety signals.  The rates of major cardiac events, malignancies, depression and suicidality at 182 weeks were comparable to those at 52 weeks.  No serious opportunistic infections, reactivation of tuberculosis, or clinically meaningful effects on laboratory measurements were reported through 182 weeks